Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22034868 | 0.85 | MEN1 (0.44) | KMT2AMEN1GAATDP1APLNR | |
| SCHEMBL335137 | 0.83 | TDP1 (0.46) | KMT2AMEN1GAAHCRTR2TDP1 | |
| SCHEMBL22395986 | 0.81 | HCRTR2 (0.41) | KMT2AMEN1GAAHCRTR2TDP1 | |
| SCHEMBL21930398 | 0.81 | MEN1 (0.41) | KMT2AMEN1GAAHCRTR2TDP1 | |
| SCHEMBL7609309 | 0.81 | MEN1 (0.41) | KMT2AMEN1GAAHCRTR2TDP1 | |
| SCHEMBL6803134 | 0.79 | EPHX1 (0.42) | KMT2AMEN1GAAHCRTR2TDP1 | |
| SCHEMBL24867843 | 0.79 | MEN1 (0.41) | KMT2AMEN1GAAHCRTR2TDP1 | |
| SCHEMBL23200870 | 0.79 | MEN1 (0.41) | KMT2AMEN1GAAHCRTR2TDP1 | |
| SCHEMBL7439320 | 0.77 | MEN1 (0.39) | KMT2AMEN1GAAHCRTR2TDP1 | |
| SCHEMBL1970278 | 0.77 | HCRTR2 (0.44) | KMT2AMEN1GAAHCRTR2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444707-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118541360-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2024-08-23 | — | — | CN | disclosed |
| US-11939318-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212150-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023107938-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4161641-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115942972-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-04-07 | — | — | CN | disclosed |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584738-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | KMT2A 1686/4885MEN1 4723/4885GAA 2206/4885 |
| US-20230212150-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | KMT2A 1686/4885MEN1 4723/4885GAA 2206/4885 |
| US-11939318-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | KMT2A 1686/4885MEN1 4723/4885GAA 2206/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | KMT2A 1686/4885MEN1 4723/4885GAA 2206/4885 |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | KMT2A 1686/4885MEN1 4723/4885GAA 2206/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | KMT2A 1686/4885MEN1 4723/4885GAA 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.